EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature

As the use of up-front osimertinib for advanced epidermal growth factor receptor (EGFR)-mutant non–small-cell lung cancer is increasing, it is important to understand the resistance pathways to the drug and subsequent treatment. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2020.05.016

Authors: Ullas Batra, Mansi Sharma, B.P. Amrith, Anurag Mehta, Parveen Jain

Review PaperKirk SmithMay 22, 2020Combination therapy, EGFR mutation, NSCLC, Personalized medicine, Resistance pathways